Zealand Pharma A/S’s first Phase III trial with dasiglucagon as a treatment for the rare pediatric disease, congenital hyperinsulinism (CHI) has met with failure, casting a shade over its prospects.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?